Quick Facts: Levmont

• Main Use: Management of allergic rhinitis (seasonal and perennial)
• Other Use: Adjunctive therapy for symptoms associated with chronic hives (urticaria)
• Respiratory Support: May be used to help manage symptoms of rhinitis that occur alongside asthma

---

Levmont is a prescription medication utilized in treatment plans to address specific allergic and respiratory conditions. Its primary use is in the management of allergic rhinitis, commonly known as hay fever, which may be seasonal or occur throughout the year (perennial). This includes providing relief from symptoms such as sneezing, runny nose, and itching of the nose and eyes.

Furthermore, this medication is indicated as a therapeutic option for patients with chronic idiopathic urticaria (hives). In this context, it may help in the reduction of symptoms like persistent itching and swelling of the skin associated with chronic hives. The drug may also be incorporated into the long-term maintenance of asthma symptoms, particularly in reducing airway inflammation associated with concurrent allergic rhinitis.

It is important to understand that Levmont is intended for chronic management and is not a rescue medicine for acute asthma attacks or severe allergic reactions. Patients should consult their healthcare professional for a complete list of indications and to determine if this therapy is appropriate for their condition. Additional information regarding the approved uses and prescribing guidelines is available through professional medical consultation.

The eligibility for Levmont is defined by official regulatory labeling, setting strict constraints based on patient age, reproductive status, and organ function.

Populations for Whom Use is Contraindicated

Use is absolutely forbidden for the following groups, as stated in the prescribing information:

• Patients with known hypersensitivity to Montelukast, Levocetirizine, Cetirizine, or any other component of the tablet.
• Patients with severe renal impairment (creatinine clearance less than 10 mL/min) or anuria (completely impaired renal function).
• Pediatric patients aged 6 to 11 years with impaired renal function.
• Patients with rare hereditary problems, such as Lapp lactase deficiency or galactose intolerance.

Age-Related and Conditional Use Restrictions

• Adults and Adolescents (15 years and older) are generally the approved population for the standard film-coated tablet strength.
• The use of the film-coated tablet is not recommended in children aged less than 6 years because its fixed dose cannot be appropriately adjusted.
• Pregnancy and Breastfeeding are generally not recommended due to a lack of adequate safety data for the combination and the known excretion of one component into breast milk.
• Caution is required for patients with predisposing factors for urinary retention or those with epilepsy and a risk of convulsions.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Levmont around pharmacokinetic and pharmacodynamic relationships, focusing on its two active components, Levocetirizine and Montelukast.

Documented Pharmacokinetic Alterations

Interactions involving the metabolism of Montelukast primarily alter its systemic exposure. Co-administration with strong enzyme inducers, such as Phenobarbital, officially results in a decrease of Montelukast plasma concentration by approximately 40%. Conversely, the strong enzyme inhibitor Gemfibrozil causes a significant increase in Montelukast exposure, documented as a 4.4-fold rise in AUC. Regarding Levocetirizine, interactions with substances like Ritonavir have been documented to potentially increase its systemic exposure and decrease its clearance.

Pharmacodynamic and Procedural Restrictions

An additive effect is officially recognized when Levocetirizine is combined with alcohol or other Central Nervous System (CNS) depressants, which may cause additional impairment of performance and alertness. For patients with aspirin-sensitive asthma, official labeling states that Montelukast therapy does not alter the necessity to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Due to the inhibitory effects of Levocetirizine, a three-day wash-out period is required before administering Allergy Skin Tests. While food does not change the extent of Levocetirizine absorption, it does decrease the rate at which it is absorbed.

Levmont is a fixed-dose combination product containing levocetirizine and montelukast, which modulate distinct inflammatory pathways.

Levocetirizine acts as a selective inverse agonist at the histamine H1 receptor (H1R). It binds to the H1 receptor and stabilizes its inactive conformation, preventing endogenous histamine from initiating signaling. This interaction consequently reduces the activation of Gq/11 proteins, decreasing intracellular IP3 (inositol triphosphate) and Ca^2+ release in effector cells, which are key downstream cascades of H1 activation.

Montelukast functions as a highly selective antagonist of the cysteinyl leukotriene receptor type 1 ( CysLT1). It competitively binds to this receptor, which is expressed on cells such as airway smooth muscle cells and eosinophils, thus blocking the binding and activity of endogenous cysteinyl leukotrienes, primarily LTD4. This blockade inhibits the Gq protein-coupled signaling pathway mediated by the CysLT1 receptor. The combined action of blocking H1 and CysLT1 receptors results in a dual-pathway modulation of systemic inflammatory responses.

Levmont is administered as a Fixed-Dose Combination (FDC) preparation, intended strictly for oral use. The standardized adult dose and typical regimen for adolescents (15 years and older) consists of one tablet (Montelukast 10 mg / Levocetirizine 5 mg) taken once per day. This standardized dosing regimen is established for continuous, long-term maintenance protocols and is not indicated for the reversal of acute asthma attacks or immediate allergic symptoms. The administration of the drug is structured around a specific daily timing.

The general principle of use requires that the single daily dose be taken in the evening. The tablets must be swallowed whole with liquid and may be administered with or without food.

Administration Principle	Detail
Route and Form	Oral Fixed-Dose Combination tablet.
Frequency Pattern	Once daily (q.d.), scheduled for evening intake.
Intake Condition	May be taken with or without food; tablet must be swallowed whole.
Procedural Constraint	Not for acute use; dedicated to continuous maintenance.

Use of this FDC strength is subject to specific population constraints. The tablet is generally not recommended for use in younger pediatric populations because the fixed combination does not allow for appropriate dose titration of the individual components. Furthermore, the use of Levmont is restricted or contraindicated in patients with severe renal impairment (Creatinine Clearance less than 10 mL/min), requiring medical supervision for less severe impairment. If a dose is missed, the schedule is typically resumed by taking the next dose at the usual time the following evening, without taking a double dose.

Research evidence / Overview of Studies for Levmont

This section provides an overview of the official research that has examined the combination of Levocetirizine and Montelukast (Levmont). The information describes the types of studies conducted and the focus of their findings, but it does not offer clinical advice or interpret how the medication might work for any individual.

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The evidence base for the combination in allergic rhinitis (seasonal and perennial) has been established through short-term randomized controlled trials (RCTs). The findings from these trials have been further examined in systematic reviews and meta-analyses that integrate data from multiple clinical sites. These studies were used in research exploring how symptoms change over time and often compared the fixed-dose combination to taking only one of the components or to an inactive substance (placebo).

In these studies, research examined outcomes related to physical discomfort by tracking symptom severity using composite scores, such as the Total Nasal Symptom Score (TNSS). The studies monitored adults and certain age groups of pediatric patients who had moderate to severe allergic rhinitis. Findings describe patterns observed in the studies related to the assessment of multiple allergic rhinitis symptoms. However, the majority of the integrated data comes from studies with limited follow-up durations—typically four weeks or less—and long-term effects are not fully established.

Evidence for Concurrent Allergic Rhinitis and Asthma

The combination was studied for patients with coexisting allergic rhinitis and mild to moderate asthma. The research examined outcomes related to systemic or functional imbalance by assessing both nasal symptoms and changes in pulmonary function. Specifically, studies monitored the change in nasal symptom scores alongside objective measures of how air moves through the lungs, such as the Forced Expiratory Volume in 1 second ( FEV1). While the evidence level for this patient group is based on high-quality studies, the studies primarily focused on short-term symptom changes and changes in functional measures. There is limited information concerning hard clinical outcomes specific to asthma management, such as the long-term frequency of asthma exacerbations.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, particularly for conditions like chronic urticaria (hives) where sample sizes were modest. Follow-up durations were limited in many of the key trials, meaning the research provides insight into short-term changes, but the durability of these patterns requires further study. Furthermore, comparative evidence is lacking for some conditions when comparing the combination directly against other high-dose or alternative treatment strategies. The studies report how symptoms evolved in the observed populations, but research does not determine whether an individual will respond similarly.

Key Studies & References

1. Evaluation of Neuropsychiatric Effects of Montelukast–Levocetirizine Combination Therapy in Children with Asthma and Allergic Rhinitis

Common questions about Levmont (FAQ)

---

Q: How long does it typically take for Levmont to start working?

The levocetirizine component has demonstrated an onset of pharmacological activity observed one hour post-intake in certain controlled trials. However, Levmont is a fixed-dose combination established for continuous, long-term maintenance rather than the treatment of acute symptoms.

---

Q: What happens if I stop taking Levmont suddenly?

Stopping the levocetirizine component may result in the recurrence of symptoms like pruritus (itching), even if itching was not present before treatment began. Furthermore, reports indicate that neuropsychiatric symptoms associated with the montelukast component have sometimes been observed to persist even after the medicine is stopped.

---

Q: Are there any common over-the-counter pain relievers that interact with Levmont?

The official documentation does not detail specific interactions between the montelukast component and Acetaminophen. However, caution is advised for any patient using other drugs that may cause central nervous system effects or consuming alcohol, as these can increase impairment when combined with the medicine’s components.

---

Q: Does Levmont help with exercise-induced symptoms?

The montelukast component is used for the prophylaxis (prevention) of exercise-induced bronchoconstriction (EIB) in certain patients. However, Levmont is established for continuous maintenance protocols and is not intended for the reversal of acute asthma or allergy symptoms.

---

Q: Can Levmont affect my ability to drive or operate machinery?

Because some patients may experience somnolence (drowsiness), fatigue, or asthenia (weakness), patients are generally advised to understand their individual response to the medicine before engaging in activities that require mental alertness, such as driving a car or operating machinery.

---

Q: What are the main research findings about Levmont's long-term use?

The majority of the research for the fixed-dose combination is based on short-term randomized controlled trials, typically with follow-up durations of four weeks or less. Due to this, official research indicates that long-term effects are not fully established.

---

Q: Does Levmont cause weight gain?

Official regulatory documentation generally does not list weight gain as a common or frequent adverse reaction for the active components. Side effects that are commonly reported include drowsiness, headache, dry mouth, and fatigue.

---

Q: Do food or certain drinks affect how well Levmont works?

The tablets may be administered with or without food. While food does not change the overall extent of exposure of the levocetirizine component, it is reported to delay the time at which the maximum concentration of the drug is reached in the body.

---

Q: Can Levmont be used to treat hives or other skin conditions?

One of the active components, levocetirizine, is officially indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (hives). However, research studying the combination product for this use reported modest sample sizes and varied evidence quality.

---

Q: Is Levmont safe for use in older adults?

Official information notes that the processing of the levocetirizine component is primarily dependent on renal (kidney) function, not chronological age. Therefore, any dosage adjustments or constraints for older patients are based on the individual’s level of kidney function, especially for those with severe impairment.

---

Q: How long after taking Levmont can I feel the maximum effect?

Peak plasma concentrations (mathrmCmax) for the levocetirizine component are typically reached approximately 0.9 hours after administration of the oral tablet. This time of maximum drug concentration does not necessarily correspond to the time of maximum symptom relief for every individual.

---

Q: Are there different strengths available for Levmont?

The standard tablet is provided as a Fixed-Dose Combination of the two active ingredients. The fixed nature of the tablet means that the doses of the individual components cannot be adjusted.

---

Q: What is the shelf life or typical expiration time for Levmont?

The expiration date on the packaging reflects the time the product remains stable, retaining its full strength and quality when stored according to the labeled conditions. Regulatory guidance requires manufacturers to provide stability testing data to support the labeled expiration date, which is verified by the authority.

---

Q: What happens if I take more Levmont than recommended?

Official reports concerning overdose with the montelukast component have cited common adverse experiences such as abdominal pain, drowsiness, headache, and vomiting. Management of overdose is typically centered on standard supportive care.

---

Q: Are the side effects of Levmont permanent?

Reports suggest that most common adverse reactions are generally reversible after treatment is stopped. However, regulatory labeling specifically notes that serious neuropsychiatric events associated with the montelukast component may persist even after treatment withdrawal.

---

Q: Are there any warnings about taking Levmont with mental health medications?

Official information recognizes an additive effect when the levocetirizine component is combined with Central Nervous System (CNS) depressants, which could lead to increased impairment. Additionally, the drug carries a separate warning for serious Neuropsychiatric Events.

---

Q: What are the physical characteristics of the Levmont pill (color, shape)?

The film-coated tablets are typically described in official product documents as being light yellow to yellow colored, round shaped, beveled edge, and biconvex.

---

Q: Why might a doctor prescribe Levmont instead of a corticosteroid?

The montelukast component is a Leukotriene Receptor Antagonist, which is not a steroid. Official labeling includes a constraint that the montelukast component is not intended to be substituted abruptly for inhaled or oral corticosteroids, as these two classes of drugs function with distinct roles in treatment pathways.

---

Q: What is the difference between Levmont and drugs ending in '-kast'?

Levmont is a Fixed-Dose Combination (FDC) that contains two active ingredients: Montelukast (a leukotriene receptor antagonist, which typically ends in '-kast') and Levocetirizine (a second-generation antihistamine). The difference is that Levmont combines the action of an LTRA with an antihistamine in a single tablet.

---

Storage Conditions

Levmont must be stored under specific environmental and temperature constraints to maintain its labeled stability. Official labeling generally requires the tablets to be stored below 25°C or below 30°C, depending on the formulation. It is mandatory to store the medicine in its original package to ensure protection from light and moisture.

Stability and Handling

The product must be kept out of the sight and reach of children for safety. For certain packaging types (e.g., HDPE bottles), the in-use stability limit is 30 days after first opening.

Disposal Instructions

Unused or expired Levmont must be disposed of in accordance with local requirements for pharmaceutical waste. The official instruction prohibits discarding the medicine via wastewater or household waste.